Phase II trial

#Clinical trial #Clinical trials #GLP-1 #Phase I trial #Phase II trial

New DDW Highlights vodcast: 10 September 2024

Every week, DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates in the DDW Highlights podcast. It is now also available in a concise vodcast format.   With the release of clinical… Read More

#News

#Clinical trial #Clinical trials #GLP-1 #Phase I trial #Phase II trial

This week in drug discovery (2-6 September) 

News round-up for 2-6 September by DDW Senior Digital Content Editor Diana Spencer. With the release of clinical study results that led some media titles to ask if semaglutide could be a ‘fountain of youth’, this week our news highlights focus on clinical trials at a variety of… Read More

#News

Urticaria or hives
#Clinical trial #Dermatology #Evommune #Phase II trial

Clinical trial investigates oral MRGPRX2 antagonist in urticaria

The first patient has been treated in a Phase II trial of EVO756 in adults with chronic inducible urticaria (CIndU). EVO756 is a highly selective small molecule antagonist of mas-related G-protein coupled receptor X2 (MRGPRX2) and could offer the potential for once-daily oral administration without the… Read More

#News

Non-small cell lung cancer
#European Commission #Lung cancer #Oncology #Phase II trial #Pierre Fabre

EC approves new combination treatment for NSCLC

The European Commission (EC) has approved Braftovi (encorafenib) in combination with Mektovi (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAFV600E mutation. The EC decision followw a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) issued on 25… Read More

#News #Regulatory

Neurons in the brain
#Neurocrine Biosciences #Neuroscience #Phase II trial #Psychiatry #Schizophrenia

Muscarinic M4 selective agonist shows promise in schizophrenia

Neurocrine Biosciences has revealed positive top-line data for its Phase II clinical study of NBI-1117568 (NBI-‘568) in adults with schizophrenia. NBI-‘568 is the first investigational, oral, muscarinic M4 selective agonist in development for this indication. The NBI-‘568-SCZ2028 dose-finding study met its primary endpoint for… Read More

#News

Monoclonal antibodies
#GLP-1 #Monoclonal antibodies #Obesity #Phase II trial #Skye Bioscience #Weight loss

Monoclonal antibody CB1 inhibitor for obesity enters Phase II trials

Skye Bioscience has started screening patients for a Phase II clinical trial (CBeyond) of its novel peripheral CB1 inhibitor, nimacimab, a negative allosteric modulating antibody. The study will assess the ability of nimacimab as a next-generation weight loss therapeutic to safely and effectively reduce weight in… Read More

#Editor's Choice #News

Woman experiencing hair loss
#Alopecia #Hair loss #Pelage Pharmaceuticals #Phase II trial

‘Molecular switch’ could reverse the effects of alopecia

A Phase IIa clinical trial has begun evaluating the safety and efficacy of Pelage Pharmaceuticals’ PP405, a novel topical small molecule, for the treatment of androgenetic alopecia (pattern baldness). The company is enrolling 60 women and men for the clinical study. PP405 is designed to reactivate… Read More

#Editor's Choice #News

Child having ultrasound on knee
#Levicept #Osteoarthritis #Phase II trial #University of Leeds

Positive results for neurotrophin-3 inhibitor in osteoarthritis

Phase II trial results for Levicept’s LEVI-04, a novel and first in class neurotrophin-3 (NT-3) inhibitor, have shown that the drug was highly effective and well tolerated. The study enrolled more than 510 participants with pain and disability due to osteoarthritis of the knee. It was… Read More

#News

Obese man measures his waist
#GlobalData #GLP-1 #Obesity #Phase II trial #Viking Therapeutics #Weight loss

Obesity drug competition expected to intensify by 2030

Viking Therapeutics’ dual GLP-1/GIP receptor agonist VK2735 could become a direct competitor to Eli Lilly’s Mounjaro/Zepbound (tirzepatide), predicts data analytics company GlobalData. In February 2024, Viking Therapeutics published Phase IIa results for its VK2735 candidate, which is being investigated both as a weekly subcutaneous… Read More

#News

Jigsaw puzzle of the brain
#Alzheimer's #Dementia #Diabetes #GLP-1 #Novo Nordisk #Phase II trial #Weight loss

GLP-1 receptor agonist slows Alzheimer’s cognitive decline

In new revelations about glucagon-like peptide-1 (GLP-1) drugs like Ozempic, a study has demonstrated the therapies could protect against dementia. In a Phase IIb trial, Novo Nordisk’s GLP-1 receptor agonist liraglutide appears to reduce shrinking in the parts of the brain that control memory, learning, language… Read More

#News #Trending News

#Cystic fibrosis #Enterprise Therapeutics #Phase II trial

Clinical trial will assess novel approach to cystic fibrosis

Enterprise Therapeutics announced it has dosed the first person with cystic fibrosis (pwCF) in its Phase IIa trial of ETD001. ETD001, a low molecular weight compound with first-in-class potential, targets the epithelial sodium channel (ENaC) in the airway epithelium to increase the hydration and clearance of… Read More

#News

Cancer research
#Amyotrophic lateral sclerosis (ALS) #Neurology #Neuroscience #Phase II trial #TikoMed

‘Encouraging’ results for potential disease-modifying ALS drug

New clinical data have shown that TikoMed’s low molecular weight dextran sulfate compound ILB is safe and well tolerated in patients with amyotrophic lateral sclerosis (ALS). The trial was carried out at the Queen Elizabeth Hospital, Birmingham, UK, by the University of Birmingham’s Drugs, Devices, Diagnostics… Read More

#Editor's Choice #News

#CatalYm #Financing #Monoclonal antibodies #Oncology #Phase II trial

CatalYm raises $150m for cancer therapy visugromab

CatalYm has completed a $150 million Series D financing to support the Phase II development of its cancer therapy visugromab. The oversubscribed round was led by new investors, Canaan Partners and Bioqube Ventures, and joined by Forbion’s Growth Opportunities Fund, Omega Funds and Gilde Healthcare. Existing investors Jeito Capital, Brandon… Read More

#Business & Investment #Cancer Research #News

#Clinical trial design #Clinical trials #Phase I trial #Phase II trial

New DDW Highlights vodcast: 15 July 2024

Every week, DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates in the DDW Highlights podcast. It is now also available in a concise vodcast format.   Clinical trial news has caught… Read More

#News

#Clinical trial design #Clinical trials #Phase I trial #Phase II trial

New DDW Highlights podcast: 15 July 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Clinical trial news has caught our attention this week. Despite the revelation… Read More

#News

#Clinical trial design #Clinical trials #Phase I trial #Phase II trial

This week in drug discovery (8-12 July) 

News round-up for 8-12 July by DDW Senior Digital Content Editor Diana Spencer. Clinical trial news has caught our attention this week. Despite the revelation from Phesi that a third of clinical trials fail at Phase II, DDW has reported positive human trial updates on therapeutics for myasthenia… Read More

#News